Endocrinology
Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.
Recent Discussions
How would you counsel patients with Type 1 or Type 2 diabetes mellitus and heart failure on the use of SGLT-2 inhibitors when they have a history of DKA?
Making a recommendation to prescribe this class will really require a case-by-case clinical assessment. It is clear that SGLT-2 inhibitors are very effective in preventing hospitalization for heart failure, and so we will want to suggest their use whenever possible. But it is also clear that DKA (mo...
How does a strong family history of breast cancer influence your decision between RAI and thyroidectomy for definitive treatment of hyperthyroidism, in light of emerging observational data suggesting a possible association between RAI and increased breast cancer risk?
There is an increased risk for solid tumors, especially breast cancer, following radioactive iodine (relative risk from 0.45-2.55). This data is strongest for those treated for thyroid cancer as opposed to Graves disease, as it is dose dependent, but studies do support an increased risk for breast c...
When would you consider using transvaginal cabergoline in the treatment of prolactinoma?
This is considered an off-label use, but I have done this a few times, and I know some of my colleagues have as well. There is not much in the literature on this, mostly case reports. I would reserve this for patients who do not tolerate the oral forms of cabergoline or bromocriptine.
Does the degree of TSH suppression significantly impact the risk of differentiated thyroid carcinoma recurrence?
This is a very timely question. The new 2025 Guidelines for thyroid cancer was just published. They cite studies that recurrence and cancer dead for low and low/ intermediate risk thyroid cancer patients are not affected by TSH suppression. The recommended TSH is normal and less than 4 uU/ml. It is ...
Can carbamazepine make thyroid function test results look spuriously abnormal?
Carbamazepine can also displace thyroid hormone from binding proteins. Although in the short term this might transiently increase free T4 (with a reciprocal decrease in TSH), thyroid function tests should normalize once an equilibrium is achieved. In some assays that rely on dilution of the sample, ...
Do you get DEXA scans routinely before starting ADT for prostate cancer or endocrine therapy for breast cancer?
When initiating long-term ADT, I order a DEXA scan, check vitamin D level, ensure adequate dietary calcium intake, and discuss weight-bearing exercise/refer to PT when appropriate. I also continue check DEXAs every 2 years unless they otherwise meet criteria for a bone-modifying agent (mCRPC with bo...
When do you check vitamin D levels in patients with depressive symptoms?
I routinely check 25-OH D in all my patients. Given that half the population is deficient and that we now know the role of vitamin D not only for bones but in mood, cognition, and immunity. We need to be aware of deficiencies and replete if low. Moreover, ideal levels are 60-80, not just over 29 as ...
How long do you typically treat patients with phentermine for weight loss and what clinical markers do you follow?
Phentermine has been available since 1959 and remains an affordable and effective medication option added to a full lifestyle-based weight management plan. In people who are generally healthy and without contraindications to the medication, I have had patients used in at least intermittently for sev...
Do you require levothyroxine to be taken on an empty stomach in patients with stable hypothyroidism, or is dosing with breakfast acceptable with dose adjustment?
Ideally, levothyroxine should be taken on empty stomach but if a patient is taking it with breakfast and has a stable normal TSH, it is okay to continue but if TSH fluctuates change to empty stomach.
Would you favor the use of denosumab over bisphosphonate therapy for treatment of osteoporosis in patients who are at high risk for osteoarthritis given recent data suggesting reduced risk of developing knee OA?
Although the overall data to date concerning the impact of denosumab to reduce incident knee OA or lessen established disease remain limited, there are sufficient signals that warrant further investigation and support the need for an appropriately powered RCT with endpoints that include both patient...